Benitec reports wider FY2026 loss; BB-301 trial updates
Benitec Biopharma reported a wider FY2026 net loss while advancing BB-301, an AAV9 gene therapy for OPMD in Phase 1b/2a. The company said low-dose cohorts had completed 12-month follow-ups and the enrolled high-dose cohort showed no safety issues; Wedbush raised its $17 target.